Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Marx, N; Imhof, A; Froehlich, J; Siam, L; Ittner, J; Wierse, G; Schmidt, A; Maerz, W; Hombach, V; Koenig, W.
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Circulation. 2003; 107(15):1954-1957
Doi: 10.1161/01.CIR.0000069272.06194.91
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- März Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Interaction of CD40L with its receptor CD40 is critically involved in inflammatory cell activation in atherogenesis. In addition, serum levels of soluble CD40L are elevated in acute coronary syndromes and have been associated with increased cardiovascular risk in healthy subjects, thus making sCD40L an intriguing target to modulate the inflammatory response in the vasculature. PPARgamma-activating thiazolidinediones, novel insulin-sensitizing antidiabetic agents, have recently been shown to exhibit antiinflammatory effects in the vessel wall. To examine whether thiazolidinedione treatment might modulate serum levels of sCD40L in high-risk patients, we performed a randomized, placebo-controlled, single-blinded trial to assess the effect of rosiglitazone on sCD40L levels in patients with type 2 diabetes and coronary artery disease (CAD). METHODS AND RESULTS: Thirty-nine patients with diabetes and angiographically proven CAD were randomized to receive rosiglitazone (4 mg BID) or placebo for 12 weeks. Baseline parameters did not significantly differ between groups. Rosiglitazone treatment, but not placebo, significantly reduced sCD40L serum levels within the first 2 weeks by 8.1% (17.1 to -32.7) (median percentage [interquartile range]; P<0.05 compared with baseline), further decreasing it by 18.4% (-5.0 to -33.1) after 6 weeks (P<0.05 compared with baseline), and by 27.5% (8.2 to -70.5) after 12 weeks (P<0.05 compared with baseline and with 2 weeks of treatment). CONCLUSIONS: Treatment with the PPARgamma-activating thiazolidinedione rosiglitazone reduces sCD40L serum levels in patients with type 2 diabetes and CAD. These data support an antiinflammatory and potentially antiatherogenic effect of thiazolidinediones.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Biological Markers - blood
- Blood Glucose - drug effects
- CD40 Ligand - blood
- Coronary Arteriosclerosis - blood
- Diabetes Mellitus, Type 2 - blood
- E-Selectin - blood
- Female - blood
- Fibrinolytic Agents - therapeutic use
- Hemoglobin A, Glycosylated - analysis
- Humans - analysis
- Hypoglycemic Agents - therapeutic use
- Male - therapeutic use
- Middle Aged - therapeutic use
- Receptors, Cytoplasmic and Nuclear - agonists
- Receptors, Interleukin-2 - blood
- Reference Values - blood
- Solubility - blood
- Thiazoles - therapeutic use
- Thiazolidinediones - therapeutic use
- Time - therapeutic use
- Transcription Factors - agonists
- Treatment Outcome - agonists
- Vasodilator Agents - therapeutic use
- Find related publications in this database (Keywords)
- diabetes mellitus
- coronary disease
- receptors